[go: up one dir, main page]

EA200100670A1 - СПОСОБ ВЫСОКОПРОДУКТИВНОЙ ЭКСПРЕССИИ АКТИВНЫХ ХИМЕРНЫХ БЕЛКОВ РЕЦЕПТОРА ЛИМФОТОКСИНА-b; И ИММУНОГЛОБУЛИНА И ИХ ВЫДЕЛЕНИЕ - Google Patents

СПОСОБ ВЫСОКОПРОДУКТИВНОЙ ЭКСПРЕССИИ АКТИВНЫХ ХИМЕРНЫХ БЕЛКОВ РЕЦЕПТОРА ЛИМФОТОКСИНА-b; И ИММУНОГЛОБУЛИНА И ИХ ВЫДЕЛЕНИЕ

Info

Publication number
EA200100670A1
EA200100670A1 EA200100670A EA200100670A EA200100670A1 EA 200100670 A1 EA200100670 A1 EA 200100670A1 EA 200100670 A EA200100670 A EA 200100670A EA 200100670 A EA200100670 A EA 200100670A EA 200100670 A1 EA200100670 A1 EA 200100670A1
Authority
EA
Eurasian Patent Office
Prior art keywords
immunoglobulin
protein
hybrids
receptor
lymphotoxin
Prior art date
Application number
EA200100670A
Other languages
English (en)
Other versions
EA005270B1 (ru
Inventor
Джеффри Браунинг
Конрад Миатковски
Вернер Мейер
Original Assignee
Байоджен, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22345666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200100670(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байоджен, Инк. filed Critical Байоджен, Инк.
Publication of EA200100670A1 publication Critical patent/EA200100670A1/ru
Publication of EA005270B1 publication Critical patent/EA005270B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

Настоящее изобретение относится к способам экспрессии с большим выходом гибридов белков и иммуноглобулина, обладающих высокой аффинностью связывания соответствующих лигандов, называемых здесь как "активная" форма, культивируя клетки-хозяева, трансформированные с помощью ДНК, кодирующей желаемые гибриды, в системе культивирования при низкой температуре, минимизируя, таким образом, количество неправильно уложенных и неправильно сшитых форм белка. Указанные клетки-хозяева могут представлять собой трансформированнные клетки млекопитающих, насекомых, дрожжей или бактерий. Гибрид белка и иммуноглобулина может содержать член семейства TNF или рецептора TNF, такой как лимфотоксин-бета или рецептор лимфотоксина-бета. Настоящее изобретение также относится к фармацевтической композиции, содержащей указанные гибриды белка и иммуноглобулина.Отчет о международном поиске был опубликован 2000.11.23.
EA200100670A 1998-12-17 1999-12-16 СПОСОБ ВЫСОКОПРОДУКТИВНОЙ ЭКСПРЕССИИ АКТИВНЫХ ХИМЕРНЫХ БЕЛКОВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β И ИММУНОГЛОБУЛИНА И ИХ ВЫДЕЛЕНИЕ EA005270B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11275298P 1998-12-17 1998-12-17
PCT/US1999/029873 WO2000036092A2 (en) 1998-12-17 1999-12-16 METHOD FOR THE HIGH LEVEL EXPRESSION OF ACTIVE LYMPHOTOXIN-β RECEPTOR IMMUNOGLOBULIN CHIMERIC PROTEINS AND THEIR PURIFICATION

Publications (2)

Publication Number Publication Date
EA200100670A1 true EA200100670A1 (ru) 2001-12-24
EA005270B1 EA005270B1 (ru) 2004-12-30

Family

ID=22345666

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100670A EA005270B1 (ru) 1998-12-17 1999-12-16 СПОСОБ ВЫСОКОПРОДУКТИВНОЙ ЭКСПРЕССИИ АКТИВНЫХ ХИМЕРНЫХ БЕЛКОВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β И ИММУНОГЛОБУЛИНА И ИХ ВЫДЕЛЕНИЕ

Country Status (27)

Country Link
US (3) US7585946B2 (ru)
EP (3) EP3006563A1 (ru)
JP (4) JP4878676B2 (ru)
KR (3) KR20070091227A (ru)
CN (2) CN100387708C (ru)
AT (1) ATE536372T1 (ru)
AU (2) AU777232B2 (ru)
BR (1) BR9916325B1 (ru)
CA (1) CA2354539A1 (ru)
CY (1) CY1117003T1 (ru)
CZ (1) CZ20012156A3 (ru)
DK (2) DK2374872T4 (ru)
EA (1) EA005270B1 (ru)
EE (1) EE200100324A (ru)
ES (1) ES2554482T5 (ru)
HK (1) HK1223398A1 (ru)
HU (1) HUP0200064A2 (ru)
IL (3) IL143670A0 (ru)
IS (1) IS5959A (ru)
NO (1) NO20012991L (ru)
NZ (3) NZ549623A (ru)
PT (1) PT2374872E (ru)
SG (1) SG123531A1 (ru)
SI (1) SI2374872T2 (ru)
SK (1) SK8552001A3 (ru)
TR (2) TR200504220T2 (ru)
WO (1) WO2000036092A2 (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
NZ510560A (en) * 1998-10-09 2003-09-26 Biogen Inc Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
US20020168367A1 (en) * 2000-04-28 2002-11-14 Planet Biotechnology Incorporated Novel immunoadhesins for treating and preventing viral and bacterial diseases
ES2332872T3 (es) 2000-04-28 2010-02-15 Planet Biotechnology, Inc. Inmunoadhesina para la prevencion de la infeccion por rinovirus.
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
DE60211329T2 (de) * 2001-01-16 2007-05-24 Regeneron Pharmaceuticals, Inc. Isolierung von sezernierte proteine exprimierenden zellen
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
PL377603A1 (pl) 2002-12-23 2006-02-06 Bristol-Myers Squibb Company Poprawa jakości produktu w hodowlach komórek ssaczych do wytwarzania białka
CN101044239B (zh) 2002-12-23 2010-12-08 布里斯托尔-迈尔斯斯奎布公司 用于蛋白质生产的哺乳动物细胞培养方法
WO2005024012A1 (en) * 2003-09-11 2005-03-17 Novozymes A/S Increased expression of a modified polypeptide
CA2548940A1 (en) * 2003-12-23 2005-07-14 Applied Research Systems Ars Holding N.V. Process for the production of tumor necrosis factor-binding proteins
US20110038854A1 (en) * 2006-03-30 2011-02-17 University Of Medicine And Dentistry Of New Jersey Strategy for homo- or hetero-dimerization of various proteins in solution and in cell
US7923011B2 (en) * 2006-10-12 2011-04-12 Genentech, Inc. Antibodies to lymphotoxin-alpha
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
KR20090071652A (ko) 2006-10-20 2009-07-01 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료
JP5431171B2 (ja) * 2007-03-15 2014-03-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 自己免疫障害の処置
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
EA201070987A1 (ru) * 2008-02-29 2011-04-29 Байоджен Айдек Ма Инк. Очищенные гибридные белки иммуноглобулина и способы их очищения
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
SG185014A1 (en) 2010-04-26 2012-11-29 Novartis Ag Improved cell cultivation process
EP2723759A4 (en) * 2011-06-24 2015-01-28 Reddys Lab Ltd Dr PURIFICATION OF CHIMERIC PROTEIN
WO2013025079A1 (en) 2011-08-17 2013-02-21 Hanwha Chemical Corporation Method for preparing active form of tnfr-fc fusion protein
JP2015531244A (ja) 2012-10-15 2015-11-02 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ タンパク質を製造するための哺乳動物細胞培養方法
TW202423993A (zh) 2012-11-14 2024-06-16 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
IL256383B2 (en) 2015-06-30 2023-03-01 Sanford Burnham Prebys Medical Discovery Inst btla fusion protein agonists and uses thereof
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
CN105400721A (zh) * 2015-12-11 2016-03-16 湖南农业大学 一种快速筛选具有抗菌活性芽孢杆菌的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2906096A (en) 1953-12-14 1959-09-29 Pacific Ind Mfg Co Precision control system for press brakes or the like
WO1991000347A1 (en) 1989-07-04 1991-01-10 Novo Nordisk A/S Method of producing proteins with fviii activity and/or fviii derivatives
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US7030080B2 (en) * 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
ES2157889T3 (es) * 1990-06-27 2001-09-01 Biogen Inc Linfotoxina complejada de superficie.
US5795964A (en) * 1990-06-27 1998-08-18 Biogen, Inc. Lymphotoxin-beta and lymphotoxin-beta complexes
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
NZ260103A (en) * 1990-11-30 1996-10-28 Bio Technology General Corp Somatotropin with alterations in the alpha-helix-1 region
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5643570A (en) * 1992-05-19 1997-07-01 Xoma Corporation BPI-immunoglobulin fusion proteins
EP0620739A4 (en) * 1992-09-15 1997-01-15 Immunex Corp Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
WO1994006478A1 (en) 1992-09-22 1994-03-31 Medin Corporation A system for securing medical tools for sterilization
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5691196A (en) * 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5726039A (en) * 1994-07-21 1998-03-10 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Vectors and transformed host cells for recombinant protein production at reduced temperatures
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
BR9708928A (pt) * 1996-05-08 2000-05-09 Hoffmann La Roche Tratamento de asma com tnfr-ig
US6040560A (en) * 1996-10-22 2000-03-21 Philip Morris Incorporated Power controller and method of operating an electrical smoking system
US7255854B1 (en) * 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
BR9712670A (pt) 1996-10-25 1999-10-19 Biogen Inc Receptores para linfotoxina-beta, anticorpos anti-receptor para linfotoxina, e anticorpos antiligante de linfotoxina como agentes terapêuticos para o tratamento de doencas imunológicas
EP0961782A4 (en) * 1996-10-30 2003-07-16 Human Genome Sciences Inc TR2 RECEPTOR OF TUMOR NECROSIS FACTOR IN MAN
EP0948543A1 (en) * 1996-12-12 1999-10-13 Genentech, Inc. Hvem polypeptides and uses thereof
US6221608B1 (en) * 1997-01-22 2001-04-24 Ortho Pharmaceutical Corporation Methods for identifying erythropoietin receptor binding protein
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
EP1071769A1 (en) * 1998-04-16 2001-01-31 Genentech, Inc. Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence
WO1999061650A1 (en) 1998-05-29 1999-12-02 Genentech, Inc. Cell culture process for producing glycoproteins
NZ510560A (en) * 1998-10-09 2003-09-26 Biogen Inc Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US9086881B2 (en) 2012-06-29 2015-07-21 Intel Corporation Mechanism for facilitating write tracking for following data eye movements across changing thermal conditions in memory systems

Also Published As

Publication number Publication date
KR20020013482A (ko) 2002-02-20
DK1141248T3 (da) 2012-03-12
IL229738A0 (en) 2014-01-30
KR20070091227A (ko) 2007-09-07
IS5959A (is) 2001-05-31
EP2374872B2 (en) 2019-02-20
JP2014239697A (ja) 2014-12-25
JP2013116118A (ja) 2013-06-13
NO20012991L (no) 2001-08-17
SI2374872T1 (sl) 2016-03-31
US20130196376A1 (en) 2013-08-01
ES2554482T3 (es) 2015-12-21
CN100387708C (zh) 2008-05-14
IL143670A0 (en) 2002-04-21
JP4878676B2 (ja) 2012-02-15
CA2354539A1 (en) 2000-06-22
BR9916325B1 (pt) 2011-06-28
CZ20012156A3 (cs) 2001-09-12
HK1038244A1 (en) 2002-03-08
NO20012991D0 (no) 2001-06-15
HK1223398A1 (en) 2017-07-28
CY1117003T1 (el) 2017-04-05
JP2010158252A (ja) 2010-07-22
EP2374872A3 (en) 2011-10-19
NZ538599A (en) 2007-11-30
AU2364400A (en) 2000-07-03
ES2554482T5 (es) 2019-07-18
BR9916325A (pt) 2001-10-02
US8709759B2 (en) 2014-04-29
NZ549623A (en) 2008-05-30
EP1141248A2 (en) 2001-10-10
KR100732934B1 (ko) 2007-06-29
EP2374872B1 (en) 2015-11-25
TR200504220T2 (tr) 2007-04-24
SG123531A1 (en) 2006-07-26
EE200100324A (et) 2002-10-15
JP5777171B2 (ja) 2015-09-09
SI2374872T2 (sl) 2019-05-31
EP3006563A1 (en) 2016-04-13
US8283138B2 (en) 2012-10-09
WO2000036092A3 (en) 2000-11-23
PL348816A1 (en) 2002-06-17
EP2374872A2 (en) 2011-10-12
US20020039580A1 (en) 2002-04-04
WO2000036092A2 (en) 2000-06-22
CN1333819A (zh) 2002-01-30
DK2374872T4 (en) 2019-04-23
JP2003517277A (ja) 2003-05-27
PT2374872E (pt) 2015-12-09
AU2005200042A1 (en) 2005-02-03
IL205698A (en) 2015-11-30
CN101289512A (zh) 2008-10-22
AU2005200042B2 (en) 2008-05-01
EA005270B1 (ru) 2004-12-30
US20100136625A1 (en) 2010-06-03
SK8552001A3 (en) 2001-12-03
HUP0200064A2 (en) 2002-05-29
AU777232B2 (en) 2004-10-07
NZ529276A (en) 2005-03-24
EP1141248B1 (en) 2011-12-07
TR200101703T2 (tr) 2002-05-21
WO2000036092A9 (en) 2002-08-22
ATE536372T1 (de) 2011-12-15
DK2374872T3 (en) 2015-12-14
US7585946B2 (en) 2009-09-08
KR20060084860A (ko) 2006-07-25

Similar Documents

Publication Publication Date Title
EA200100670A1 (ru) СПОСОБ ВЫСОКОПРОДУКТИВНОЙ ЭКСПРЕССИИ АКТИВНЫХ ХИМЕРНЫХ БЕЛКОВ РЕЦЕПТОРА ЛИМФОТОКСИНА-b; И ИММУНОГЛОБУЛИНА И ИХ ВЫДЕЛЕНИЕ
Sumikawa et al. Active multi-subunit ACh receptor assembled by translation of heterologous mRNA in Xenopus oocytes
DD148235A5 (de) Verfahren zur herstellung eines ausgewaehlten proteins
NO982672L (no) FremgangsmÕte for fremstilling av rekombinante proteiner i E. coli ved fermentering med h°y celletetthet
Lane et al. The Xenopus Oocyte as a Surrogate Secretory System The Specificity of Protein Export
EP0256321A1 (de) Expressionsprodukte des menschilchen Papillomvirus Typ 18, für diese Proteine spezifische Antikörper und diese Antikörper bzw. entsprechende DNA enthaltende Diagnostika
WO2000034474A3 (en) Growth factor homolog zvegf3
DE69132814D1 (de) Neues insulinähnliches wachstumsfaktor bindendes protein igfbp-5
JPS61501152A (ja) ヒトのエリトロポエチンｃＤＮＡクロ−ン
IE852681L (en) Monoclonal antibodies for cancer
CA2086131A1 (en) Anti-human ige monoclonal antibodies
ATE208815T1 (de) Genetisches igfbp-5 rodierendes material
DE69101008T2 (de) Ig-g bindendes protein.
Murtaugh et al. [15] Posttranslational modification of calmodulin
Piñol-Roma et al. Purification and characterization of proteins of heterogeneous nuclear ribonucleoprotein complexes by affinity chromatography
Masuoka et al. Preparative isoelectric focusing and preparative electrophoresis of hydrophobic Candida albicans cell wall proteins with in‐line transfer to polyvinylidene difluoride membranes for sequencing
RU2336279C2 (ru) БЕЛОК IFNAB-BPI, ЕГО ПРЕДШЕСТВЕННИК, МОЛЕКУЛА ДНК, ЭКСПРЕССИРУЮЩИЙ ВЕКТОР, СПОСОБ ПРОДУЦИРОВАНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ IFN-α ИЛИ IFN-β
Brinegar et al. Resolution of the subunit composition of a cytokinin-binding protein from wheat embryos
Eilat et al. Antibodies to native tRNA in NZB/NZW mice
Bagshaw DNA-dependent RNA polymerases from Artemia salina. Subunit structure of polymerase II
Chan et al. Purification of a phosphoprotein from chromatin of rat liver
Del Portillo et al. Immunochemical analysis of baboon (Papio cynocephalus) IgG subclasses
Chumakov et al. Localization of VirB1 protein on the agrobacterial cell surface
Karkhanis et al. Antigenic subunit of the polypeptide antigenic complex of the Melvin strain of Neisseria gonorrhoeae
Smolyaninov et al. Use of monoclonal antibodies to purify E. coli ribonuclease.

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent

Designated state(s): AM AZ BY KZ KG MD TJ TM RU

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU